Cargando…

Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era

INTRODUCTION: The CRASH-2 trial demonstrated that tranexamic acid (TXA) reduced mortality with no increase in adverse events in severely injured adults. TXA has since been widely used in injured adults worldwide. Our objective was to estimate mortality and adverse events in adults with trauma receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Benipal, Simranjeet, Santamarina, John-Lloyd, Vo, Linda, Nishijima, Daniel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526890/
https://www.ncbi.nlm.nih.gov/pubmed/31123544
http://dx.doi.org/10.5811/westjem.2019.4.41698
_version_ 1783419962408304640
author Benipal, Simranjeet
Santamarina, John-Lloyd
Vo, Linda
Nishijima, Daniel K.
author_facet Benipal, Simranjeet
Santamarina, John-Lloyd
Vo, Linda
Nishijima, Daniel K.
author_sort Benipal, Simranjeet
collection PubMed
description INTRODUCTION: The CRASH-2 trial demonstrated that tranexamic acid (TXA) reduced mortality with no increase in adverse events in severely injured adults. TXA has since been widely used in injured adults worldwide. Our objective was to estimate mortality and adverse events in adults with trauma receiving TXA in studies published after the CRASH-2 trial. METHODS: We systematically searched PubMed, Embase, MicroMedex, and ClinicalTrials.gov for studies that included injured adults who received TXA and reported mortality and/or adverse events. Two reviewers independently assessed study eligibility, abstracted data, and assessed the risk of bias. We conducted meta-analyses using random effects models to estimate the incidence of mortality at 28 or 30 days and in-hospital thrombotic events. RESULTS: We included 19 studies and 13 studies in the systematic review and meta-analyses, respectively. The pooled incidence of mortality at 28 or 30 days (five studies, 1538 patients) was 10.1% (95% confidence interval [CI], 7.8–12.4%) (vs 14.5% [95% CI, 13.9–15.2%] in the CRASH-2 trial), and the pooled incidence of in-hospital thrombotic events (nine studies, 1656 patients) was 5.9% (95% CI, 3.3–8.5%) (vs 2.0% [95% CI, 1.8–2.3%] in the CRASH-2 trial). CONCLUSION: Compared to the CRASH-2 trial, adult trauma patients receiving TXA identified in our systematic review had a lower incidence of mortality at 28 or 30 days, but a higher incidence of in-hospital thrombotic events. Our findings neither support nor refute the findings of the CRASH-2 trial but suggest that incidence rates in adults with trauma in settings outside of the CRASH-2 trial may be different than those observed in the CRASH-2 trial.
format Online
Article
Text
id pubmed-6526890
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Department of Emergency Medicine, University of California, Irvine School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-65268902019-05-23 Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era Benipal, Simranjeet Santamarina, John-Lloyd Vo, Linda Nishijima, Daniel K. West J Emerg Med Trauma INTRODUCTION: The CRASH-2 trial demonstrated that tranexamic acid (TXA) reduced mortality with no increase in adverse events in severely injured adults. TXA has since been widely used in injured adults worldwide. Our objective was to estimate mortality and adverse events in adults with trauma receiving TXA in studies published after the CRASH-2 trial. METHODS: We systematically searched PubMed, Embase, MicroMedex, and ClinicalTrials.gov for studies that included injured adults who received TXA and reported mortality and/or adverse events. Two reviewers independently assessed study eligibility, abstracted data, and assessed the risk of bias. We conducted meta-analyses using random effects models to estimate the incidence of mortality at 28 or 30 days and in-hospital thrombotic events. RESULTS: We included 19 studies and 13 studies in the systematic review and meta-analyses, respectively. The pooled incidence of mortality at 28 or 30 days (five studies, 1538 patients) was 10.1% (95% confidence interval [CI], 7.8–12.4%) (vs 14.5% [95% CI, 13.9–15.2%] in the CRASH-2 trial), and the pooled incidence of in-hospital thrombotic events (nine studies, 1656 patients) was 5.9% (95% CI, 3.3–8.5%) (vs 2.0% [95% CI, 1.8–2.3%] in the CRASH-2 trial). CONCLUSION: Compared to the CRASH-2 trial, adult trauma patients receiving TXA identified in our systematic review had a lower incidence of mortality at 28 or 30 days, but a higher incidence of in-hospital thrombotic events. Our findings neither support nor refute the findings of the CRASH-2 trial but suggest that incidence rates in adults with trauma in settings outside of the CRASH-2 trial may be different than those observed in the CRASH-2 trial. Department of Emergency Medicine, University of California, Irvine School of Medicine 2019-05 2019-04-26 /pmc/articles/PMC6526890/ /pubmed/31123544 http://dx.doi.org/10.5811/westjem.2019.4.41698 Text en Copyright: © 2019 Benipal et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Trauma
Benipal, Simranjeet
Santamarina, John-Lloyd
Vo, Linda
Nishijima, Daniel K.
Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title_full Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title_fullStr Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title_full_unstemmed Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title_short Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era
title_sort mortality and thrombosis in injured adults receiving tranexamic acid in the post-crash-2 era
topic Trauma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526890/
https://www.ncbi.nlm.nih.gov/pubmed/31123544
http://dx.doi.org/10.5811/westjem.2019.4.41698
work_keys_str_mv AT benipalsimranjeet mortalityandthrombosisininjuredadultsreceivingtranexamicacidinthepostcrash2era
AT santamarinajohnlloyd mortalityandthrombosisininjuredadultsreceivingtranexamicacidinthepostcrash2era
AT volinda mortalityandthrombosisininjuredadultsreceivingtranexamicacidinthepostcrash2era
AT nishijimadanielk mortalityandthrombosisininjuredadultsreceivingtranexamicacidinthepostcrash2era